Johnson & Johnson (J&J), for the clinical trials test Covid-19 vaccine, has randomly assigned healthy adults ages 18-55 years and persons aged 65 and above to receive a high or low dose of its vaccine or a placebo.
Most volunteers who get vaccinated have produced detectable neutralizing antibodies, showing the immune system has responded very well, regardless of vaccine dose or age group, and it remained stable for at least 71 days in the age group between 18 and 55 years, according to trial data published Wednesday.
Trial data also stated that the most common side effects founded in those volunteers were fever, fatigue, headache, muscle aches and pain at the injection spot.
Chief scientific officer at J&J Dr. Paul Stoffels said that a single shot of J&J vaccine is enough to give “sustainable antibodies” and the company expects to release phase three trial results within this month.
However, the J&J vaccine has yet to be approved in the US, but the States official anticipated the authorization of the vaccine as early as next month, the third vaccine approved for use behind the Pfizer-BioTech and Moderna.